Outcome of patients with PIV infection within 30 days of diagnosis
| Characteristic . | Patients who died within 30 days of PIV infection (n = 16), N (%) . | Patients who survived > 30 days of PIV infection (n = 171), N (%) . | Univariate analysis (P) . |
|---|---|---|---|
| Age ≥ 65 y | 4 (25) | 24 (14) | .27 |
| Relapse or refractory stage of underlying malignancy | 11/16 (69) | 48/170 (28) | .0009 |
| HSCT recipients | 8 (50) | 100 (58) | .51 |
| GVHD | 4/8 (50) | 38/100 (38) | .71 |
| Neutropenia (ANC < 500 μ/L) within a week of diagnosis to resolution of symptoms | 11/16 (69) | 64/167 (38) | .018 |
| Lymphopenia (ALC < 200 μ/L) within a week of diagnosis to resolution of symptoms | 12/16 (75) | 90/167 (54) | .1 |
| APACHE II score at diagnosis, median (range) | 20 (9-30) | 11 (3-24) | < .0001 |
| Steroid use | |||
| Corticosteroids | 9 (56) | 103 (60) | .76 |
| Prednisolone ≥ 600 mg | 8 (50) | 63 (37) | .3 |
| Chemotherapy within a month of diagnosis of PIV infection | 12 (75) | 96 (56) | .14 |
| Respiratory coinfections within a month of diagnosis of PIV infection | 9 (56) | 47 (27) | .023 |
| Antiviral therapy | 5 (31) | 48 (28) | .78 |
| Aerosolized ribavirin with or without IVIG | 2 (13) | 17 (10) | .67 |
| IVIG with or without ribavirin | 5 (31) | 38 (22) | .53 |
| Characteristic . | Patients who died within 30 days of PIV infection (n = 16), N (%) . | Patients who survived > 30 days of PIV infection (n = 171), N (%) . | Univariate analysis (P) . |
|---|---|---|---|
| Age ≥ 65 y | 4 (25) | 24 (14) | .27 |
| Relapse or refractory stage of underlying malignancy | 11/16 (69) | 48/170 (28) | .0009 |
| HSCT recipients | 8 (50) | 100 (58) | .51 |
| GVHD | 4/8 (50) | 38/100 (38) | .71 |
| Neutropenia (ANC < 500 μ/L) within a week of diagnosis to resolution of symptoms | 11/16 (69) | 64/167 (38) | .018 |
| Lymphopenia (ALC < 200 μ/L) within a week of diagnosis to resolution of symptoms | 12/16 (75) | 90/167 (54) | .1 |
| APACHE II score at diagnosis, median (range) | 20 (9-30) | 11 (3-24) | < .0001 |
| Steroid use | |||
| Corticosteroids | 9 (56) | 103 (60) | .76 |
| Prednisolone ≥ 600 mg | 8 (50) | 63 (37) | .3 |
| Chemotherapy within a month of diagnosis of PIV infection | 12 (75) | 96 (56) | .14 |
| Respiratory coinfections within a month of diagnosis of PIV infection | 9 (56) | 47 (27) | .023 |
| Antiviral therapy | 5 (31) | 48 (28) | .78 |
| Aerosolized ribavirin with or without IVIG | 2 (13) | 17 (10) | .67 |
| IVIG with or without ribavirin | 5 (31) | 38 (22) | .53 |